STOCK TITAN

BioRestorative Therapies, Inc. - BRTX STOCK NEWS

Welcome to our dedicated page for BioRestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on BioRestorative Therapies stock.

BioRestorative Therapies, Inc. (NASDAQ: BRTX) is a cutting-edge biotechnology company based in the United States, dedicated to developing regenerative medicine products and therapies using cell and tissue protocols, particularly involving adult stem cells. The company’s core focuses are its Disc/Spine Program and Metabolic Program.

In the Disc/Spine Program, their lead cell therapy candidate, BRTX-100, is formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow. This innovative treatment is designed for the non-surgical management of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. BRTX-100 undergoes a meticulous production process, starting from the collection of a patient’s bone marrow, followed by the isolation and culturing of stem cells, and finally cryopreserving these cells. The therapy involves injecting BRTX-100 into the patient's damaged disc, offering hope for patients whose pain has not been alleviated by other non-invasive treatments.

The Metabolic Program focuses on developing cell-based therapies to combat obesity and metabolic disorders using brown adipose-derived stem cells. This innovative approach aims to generate brown adipose tissue to help address these widespread health issues.

BioRestorative Therapies is also venturing into the rapidly growing bio-cosmeceutical market. The company recently signed a five-year exclusive supply agreement with Cartessa Aesthetics, LLC, a prominent North American aesthetics company. This partnership aims to introduce proprietary cell-based innovations to the aesthetics market, leveraging both BioRestorative’s expertise in cell-based biologics and Cartessa’s strong market presence.

Financially, BioRestorative is strong, ending 2023 with around $11.1 million in cash and cash equivalents, and an additional $7.6 million from a recent private placement. This solid financial standing, combined with expected revenues from its new commercial products, allows the company to pursue further advancements in their clinical and preclinical pipelines, including their BRTX-100 and ThermoStem® programs.

For more information, visit BioRestorative Therapies or contact Investor Relations at ir@biorestorative.com.

Rhea-AI Summary

BioRestorative Therapies, Inc. will report its first quarter 2024 financial results on May 14, 2024, after market close. The company will discuss a new commercial agreement and provide updates on its Phase 2 clinical trial in Spine and preclinical development program in Obesity. CEO Lance Alstodt will host the quarterly conference call to review the financial results and business progress.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.52%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.52%
Tags
none
-
Rhea-AI Summary
BioRestorative Therapies announces FDA clearance of Phase 2 BRTX-100 clinical study protocol amendment, replacing saline injections with sham injections in the control group. The amendment aims to enhance safety and prevent transient clinical outcomes, maintaining the 2024 enrollment completion target.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
Rhea-AI Summary
BioRestorative Therapies, Inc. announces collaboration with Galen Patient Recruitment, Inc. to accelerate patient enrollment in Phase 2 study of BRTX-100 for chronic lumbar disc disease. Recent enhancements triple monthly trial capacity, with enrollment expected to be completed in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.76%
Tags
partnership clinical trial
-
Rhea-AI Summary
BioRestorative Therapies, Inc. announces the filing of a registration statement on Form S-1 with the SEC for the resale of up to 2,513,686 shares of common stock by selling securityholders. The filing covers shares issuable pursuant to previously issued warrants, with the registration statement not yet effective. The Company is not offering shares directly to the public at this time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
none
-
Rhea-AI Summary
BioRestorative Therapies, Inc. announced the filing of its Form 10-K annual report for 2023, highlighting its lead clinical-stage cell therapy candidate, BRTX-100, and ThermoStem® program. Positive preliminary data from the Phase 2 study of BRTX-100 in treating chronic lumbar disc disease was presented, showing encouraging results. The company also received four notices of allowance for its ThermoStem® program, indicating progress in patent approvals. Financially, BioRestorative reported a net loss decrease of 22% for 2023, with $11.07 million in cash, cash equivalents, and investments at year-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
Rhea-AI Summary
BioRestorative Therapies, Inc. announces its participation in the 36th Annual ROTH Conference. The company's CEO will engage in a fireside chat and one-on-one meetings with investors. The event will be held from March 17-19, 2024, at the Ritz Carlton, Laguna Niguel in California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
conferences
-
Rhea-AI Summary
BioRestorative Therapies (BRTX) is advancing its lead candidate, BRTX-100, a cell-based therapy for chronic lumbar disc disease. The recent data presented at the ORS 2024 Annual Meeting showed positive trends in pain and function improvements. The therapy uses autologous stem cells manufactured in a low oxygen environment to mimic disc conditions. If successful, BRTX-100 could revolutionize disc-related pain treatment with its personalized, minimally invasive approach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
none
-
Rhea-AI Summary
BioRestorative Therapies, Inc. announced agreements with certain holders of its existing warrants to exercise their warrants at a reduced price, generating approximately $8.1 million in gross proceeds. The reduction of the exercise price and issuance of new warrants was structured as an at-market transaction under Nasdaq rules. The new warrants will be exercisable into an aggregate of up to 2,513,685 shares of common stock, at an exercise price of $2.43 per share, and have a term of exercise equal to five years. The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended, or applicable under state securities laws.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-54.49%
Tags
none
Rhea-AI Summary
BioRestorative Therapies, Inc. announced preliminary 26 and 52-week blinded data from the ongoing Phase 2 clinical trial of their lead clinical candidate, BRTX-100, in subjects with chronic lumbar disc disease. The data presented at the Orthopaedic Research Society 2024 Annual Meeting showed positive trends in pain and function scales compared to baseline, indicating meaningful signals in patients enrolled in the study. The company also reported no notable safety signals, and the FDA will use the data to determine whether the trial will be allowed to proceed and ultimately gain Biologics License Application (BLA) approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.21%
Tags

FAQ

What is the current stock price of BioRestorative Therapies (BRTX)?

The current stock price of BioRestorative Therapies (BRTX) is $1.55 as of December 20, 2024.

What is the market cap of BioRestorative Therapies (BRTX)?

The market cap of BioRestorative Therapies (BRTX) is approximately 9.9M.

What does BioRestorative Therapies, Inc. specialize in?

BioRestorative Therapies, Inc. specializes in developing regenerative medicine products and therapies using adult stem cells.

What are the main programs developed by BioRestorative Therapies?

The main programs are the Disc/Spine Program and the Metabolic Program, focusing on non-surgical treatment of lumbar disc disease and cell-based therapies for obesity and metabolic disorders, respectively.

What is BRTX-100?

BRTX-100 is a cell therapy product formulated from autologous cultured mesenchymal stem cells intended for the non-surgical treatment of chronic lumbar disc disease.

How does BRTX-100 work?

BRTX-100 involves injecting cultured stem cells into a patient’s damaged disc to alleviate pain caused by protruding and bulging lumbar discs.

What recent partnership has BioRestorative Therapies entered into?

BioRestorative Therapies has signed a five-year exclusive supply agreement with Cartessa Aesthetics to bring cell-based innovations to the aesthetics market.

How financially stable is BioRestorative Therapies?

BioRestorative ended 2023 with approximately $11.1 million in cash and cash equivalents, supplemented by $7.6 million from a private placement.

What are the potential benefits of the partnership with Cartessa Aesthetics?

The partnership aims to commercialize proprietary cell-based products in the aesthetics market, potentially generating significant revenue for BioRestorative.

What is the focus of BioRestorative's Metabolic Program?

The Metabolic Program focuses on developing cell-based therapies for obesity and metabolic disorders using brown adipose-derived stem cells.

Who can I contact for investor relations at BioRestorative Therapies?

You can contact Investor Relations at BioRestorative Therapies by emailing ir@biorestorative.com.

Where can I find more information about BioRestorative Therapies?

More information can be found on their website at www.biorestorative.com.

BioRestorative Therapies, Inc.

Nasdaq:BRTX

BRTX Rankings

BRTX Stock Data

9.94M
5.08M
26.61%
13.74%
1.08%
Biotechnology
Services-misc Health & Allied Services, Nec
Link
United States of America
MELVILLE